Skip to main navigation
logo
  • Overview
  • Shareholder Information
    • Stock Quote & Chart
    • Financial Filings
    • Shareholder Structure
    • Shareholder Structure (NL)
    • Prospectus
    • Prospectus (NL)
    • Shareholder Meetings
    • Analyst Coverage
    • Transparency Notifications
    • Conversion Table
    • Conversion Table (NL)
  • Events & Presentations
  • News
  • Corporate Governance
    • Governance Overview
    • Governance Overview (NL)
    • Board of Directors
    • Management
  • IR Contact
    • Email Alerts
    • Contact IR

News

News

June 1, 2023
Oxurion to Participate in Upcoming Conferences
PDF Version
May 25, 2023
Oxurion Reaches Enrollment Target in KALAHARI Phase 2, Part B Trial of Novel PKal Inhibitor THR-149 in Diabetic Macular Edema
PDF Version
May 22, 2023
Oxurion Issues EUR 2.0 million in Bonds for Tranche 2 of the Funding Program with Atlas Special Opportunities LLC
PDF Version
May 15, 2023
Oxurion Announces Results of the Annual Shareholders’ Meeting of 2 May 2023
PDF Version
April 27, 2023
Oxurion Issues EUR 2.0 million in Bonds for Tranche 1 (B) of the Funding Program with Atlas Special Opportunities LLC
PDF Version
March 31, 2023
Oxurion Publishes 2022 Annual Report
EN
NL
March 20, 2023
Oxurion Issues EUR 2.8 million in Bonds for Tranche 1 (A) of Funding Program with Atlas Special Opportunities LL
PDF Version
March 14, 2023
Oxurion Provides Update on Recruitment for KALAHARI Phase 2, Part B Trial of Novel PKal Inhibitor THR-149 in Diabetic Macular Edema and Announces Board Changes
EN
March 2, 2023
Oxurion Announces Subscription Agreement with Atlas Providing the Company with Up To €20 Million in Funding
EN
March 2, 2023
Funding Program between Oxurion and Negma Ends
EN

Pagination

  • Current page 1
  • Page 2
  • Next page next ›
  • Last page last »
Displaying 1 - 10 of 12

Section Title

  • Who We Are
  • THR-149
  • News & Events
  • Let’s Talk

Connect with Us

  • LinkedIn
  • Twitter
  • Ⓒ2023 Oxurion NV. All rights reserved.